Holen Sie sich die Stockscreener-App
2.86
1.72%
-0.05
Handel nachbörslich:
2.88
0.02
+0.70%
Schlusskurs vom Vortag:
$2.91
Offen:
$2.91
24-Stunden-Volumen:
2.77M
Relative Volume:
1.09
Marktkapitalisierung:
$318.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-167.86M
KGV:
-1.247
EPS:
-2.2935
Netto-Cashflow:
$-132.31M
1W Leistung:
-8.63%
1M Leistung:
+6.72%
6M Leistung:
+4.38%
1J Leistung:
+118.32%
1-Tages-Spanne:
$2.78
$2.94
1-Wochen-Bereich:
$2.78
$3.25
52-Wochen-Spanne:
$1.11
$3.78
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.86 | 323.95M | 0 | -167.86M | -132.31M | -2.2935 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace
CABA Forms Agreement with Cellares for Cost-Effective Cell Thera - GuruFocus
CABA Gains Strategic Partnership for Efficient Rese-Cel Producti - GuruFocus
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com Canada
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - The Manila Times
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Canada
10-year rese-cel supply deal aims for thousands of patients a year - Stock Titan
Cabaletta Bio (NASDAQ: CABA) targets 600M authorized shares and equity plan changes - Stock Titan
Cabaletta Bio shares climb after insider purchases - MSN
Cabaletta Bio, Inc. to Present New Data on Rese-cel at ASGCT 2026 Annual Meeting - Quiver Quantitative
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting - The Manila Times
New autoimmune cell therapy data lead Cabaletta's Boston meeting talks - Stock Titan
OneIM Acquisition Corp. (OIM) - Minichart
Cabaletta (CABA) Moat Analysis | Cabaletta Bio Inc. beats EPS estimates by 15.6%High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Cabaletta Bio slides on proposed securities offering - MSN
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo
Cabaletta Bio’s Rese-cel: Transforming Autoimmune Disease Treatment with CD19-CAR T Cell Therapy, No Preconditioning, and Automated Manufacturing 1 - Minichart
Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans - TipRanks
Cabaletta Bio posts April 2026 corporate presentation highlighting rese-cel trial progress, no-preconditioning data and automated manufacturing plans - TradingView
Rese-cel data expands across autoimmune diseases at Cabaletta Bio (CABA) - Stock Titan
Cabaletta reports results, advances Rese-Cel autoimmune program - MSN
Wall Street Zen Downgrades Cabaletta Bio (NASDAQ:CABA) to Sell - MarketBeat
Cabaletta Bio (Nasdaq: CABA) asks shareholders to double authorized common stock - Stock Titan
CABA News | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Cellares’ Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy (CABA:NASDAQ) - Seeking Alpha
CABA: Cabaletta Bio Advances CAR T Cell Therapy with Cellares' Technology - GuruFocus
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - 01net
Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform - National Today
Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle - TipRanks
Cabaletta Bio's Rese-cel Made on Cellares' Platform Given to First Patients - marketscreener.com
First patients dosed with Cabaletta Bio's rese-cel manufactured on Cellares' automated cell shuttle(TM) platform - marketscreener.com
First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform - TradingView
Cellares and Cabaletta Bio Successfully Infuse First Patients with Rese-cel - Intellectia AI
Aug Retail: What is Cabaletta Bio Incs P E ratio telling usLayoff News & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aug Wrap: Is Cabaletta Bio Inc stock trending bullishWeekly Stock Recap & Momentum Based Trading Ideas - baoquankhu1.vn
Cabaletta Bio (CABA) upgraded to buy: Here's what you should know - MSN
Institution Moves: Whats the MACD signal for Cabaletta Bio IncLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Cabaletta Bio, Inc. $CABA Position Raised by JPMorgan Chase & Co. - MarketBeat
Cabaletta Bio, Inc. (CABA) Stock Forecasts - Yahoo! Finance Canada
Volume Report: Can Cabaletta Bio Inc deliver consistent dividendsMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Cabaletta Bio, Inc. (CABA) Stock forecasts - Yahoo Finance UK
H.C. Wainwright Remains a Buy on Cabaletta Bio (CABA) - The Globe and Mail
CABA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Cabaletta Reports Results, Advances Rese-Cel Autoimmune Program - MyChesCo
Aug Summary: Can Cabaletta Bio Inc disrupt its industryBuy Signal & Low Drawdown Investment Ideas - baoquankhu1.vn
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):